U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis Drug

(MedPage Today) -- A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull...